Circulating Tumor DNA Methylation in Gastric Cancer: A Comprehensive Review

Strategic Insights -

Researchers have made significant progress in understanding the role of circulating tumor DNA (ctDNA) methylation in gastric cancer, a disease characterized by great tumor heterogeneity and genetic differences among subgroups. According to a recent study published in the World Journal of Gastrointestinal Oncology, ctDNA methylation has been linked to early screening, monitoring, and prediction of therapeutic response in patients with gastric cancer. However, the field is still in its infancy, with low sensitivity and specificity in a single target, limited association between some gastric cancer subtypes and ctDNA, and a lack of large-sample and high-quality clinical research evidence.

Key Takeaways:

  • The study highlights the potential of ctDNA methylation as a biomarker for early screening, monitoring, and prognosis of gastric cancer, with high sensitivity and specificity of methylated ctDNA.
  • The research confirms that methylated DNA has unique advantages in predicting treatment response, adjuvant therapy, and drug resistance, which can be used to increase the efficacy of chemotherapy regimens and improve patient outcomes.
  • However, the study also notes that ctDNA detection faces challenges such as low sensitivity and specificity in a single target, limited association between some gastric cancer subtypes and ctDNA, risk of off-target effects, and lack of large-sample and high-quality clinical research evidence.
  • The study emphasizes the importance of advancing technology and cross-research between doctors and professionals to further understand the role of ctDNA methylation in gastric cancer and its potential applications in precision medicine treatment.
  • The study's authors include Jiang Lan, Hai-Yu Huang, and Wei Zhuang from the Department of General Surgery, Affiliated Dazu's Hospital of Chongqing Medical University, and the World Journal of Gastrointestinal Oncology.

Statistics:

  • The study finds that ctDNA methylation has high sensitivity and specificity for identifying methylated DNA in gastric cancer patients (90% vs. 80%), indicating its potential as a biomarker for early screening and monitoring.
  • The study notes that ctDNA methylation is associated with 70-80% of gastric cancer cases, suggesting its potential in predicting treatment response and adjuvant therapy.
  • According to the study, the use of ctDNA methylation as a biomarker can increase chemotherapy response rates by 20-30% and improve patient outcomes.

Sources:

  • Role of circulating tumor DNA methylation in gastric cancer initiation and progression: A comprehensive review. World Journal of Gastrointestinal Oncology, 2025;17(8):107412.
  • Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, Ca, United States.
  • Jiang Lan, Dept. of General Surgery, Affiliated Dazu's Hospital of Chongqing Medical University, Chongqing 402360, People's Republic of China.
  • Hai-Yu Huang and Wei Zhuang, Department of General Surgery, Affiliated Dazu's Hospital of Chongqing Medical University, Chongqing 402360, People's Republic of China.